Authors
Loading...
Observational analysis demonstrated Urolithin A increases IL-10 and decreases IL-6 production in MS patients, implying potential therapeutic effects.
Kukushkina et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: